Ribo Life Science Sets 27 Aug 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend
Bulletin Express
Aug 17
Ribo Life Science has scheduled a board meeting for Thursday, 27 August 2026. Directors will review and approve the unaudited results for the six months ended 30 June 2026, decide on the timing of their publication, and discuss a potential interim dividend.
The meeting agenda also includes any additional business matters that may arise.
As of the announcement date (17 August 2026), the Board comprises three executive directors—Dr. Liang Zicai (Chairman), Dr. Gan Liming and Dr. Zhang Hongyan—three non-executive directors—Dr. Qi Fei, Mr. Li Dongfang and Mr. Li Yuhui—and three independent non-executive directors—Dr. Yu Xuefeng, Mr. Ma Chaosong and Mr. Wang Ruiping.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.